Director of TScan Therapeutics Barbara Klencke Buys 18% More Shares
Director of TScan Therapeutics Barbara Klencke Buys 18% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the TScan Therapeutics, Inc. (NASDAQ:TCRX) Director, Barbara Klencke, recently bought US$56k worth of stock, for US$5.61 per share. While we're hesitant to get too excited about a purchase of that size, we do note it increased their holding by a solid 18%.
虽然这可能不是一件大事,但我们认为很高兴看到TScan Therapeutics, Inc. (纳斯达克代码:TCRX)的董事Barbara Klencke最近以每股5.61美元的价格购买了5.6万美元的股票。虽然我们对这种规模的购买持有保留态度,但我们注意到这增加了他们18%的持股。
TScan Therapeutics Insider Transactions Over The Last Year
过去一年中,TScan Therapeutics的内部交易中最大的单笔购买交易是内部交易人员Timothy Barberich以每股4.97美元的价格购买了14.2万美元的股票。尽管这次购买的价格比最近的股价(5.69美元)要低得多,但我们仍然认为内部人员的购买是积极的。虽然这表明内部人员认为该股在较低价格时被低估,但这笔交易并没有告诉我们他们对当前价格的看法。
In the last twelve months, the biggest single purchase by an insider was when insider Timothy Barberich bought US$142k worth of shares at a price of US$4.97 per share. Even though the purchase was made at a significantly lower price than the recent price (US$5.69), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
在过去十二个月里,内部人员购买了4.415万股,共计22.4万美元。但内部人员卖出了0.75万股,价值4.3万美元。总体而言,TScan Therapeutics的内部人员在过去一年中是净买入者。下图显示了过去一年中内部交易(由公司和个人)的情况。如果您想确切地知道谁以什么价格和何时出售,只需点击下面的图表!
In the last twelve months insiders purchased 44.15k shares for US$224k. But insiders sold 7.50k shares worth US$43k. Overall, TScan Therapeutics insiders were net buyers during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在过去十二个月内,TScan Therapeutics的内部人员购买了44,150股股票,总额达到22.4万美元。但内部人员卖出了7,500股,总价值43,000美元。总体而言,TScan Therapeutics的内部人员在过去一年中是净买家。下图显示了过去一年内内部人员(包括公司和个人)的交易情况。如果您想知道具体是谁以及以何种价格和时间出售,请点击下面的图表!
![1724925617099](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240829/43057831-0-eb9ac52a28d91f5146039d6d610c745d.webp/bigjpg)
TScan Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
TScan Therapeutics不是唯一股票内部人士在购买的公司。请看一下这个免费的由内部人士购买的潜力公司列表。
Insider Ownership
内部人员持股情况
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests TScan Therapeutics insiders own 0.8% of the company, worth about US$2.3m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We prefer to see high levels of insider ownership.
测试公司领导者与其他股东之间的一致性的另一种方法是看看他们拥有多少股份。如果内部人士在公司拥有大量股份,我认为这是一个好迹象。我们的数据显示,TScan Therapeutics的内部人士拥有该公司0.8%的股份,价值约230万美元。但需要注意的是,内部人士有可能通过私人公司或其他公司结构间接持有股权。我们更希望看到高水平的内部持股。
So What Do The TScan Therapeutics Insider Transactions Indicate?
那么,TScan Therapeutics内部交易的意义是什么呢?
Our data shows a little insider buying, but no selling, in the last three months. That said, the purchases were not large. However, our analysis of transactions over the last year is heartening. While we have no worries about the insider transactions, we'd be more comfortable if they owned more TScan Therapeutics stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. While conducting our analysis, we found that TScan Therapeutics has 2 warning signs and it would be unwise to ignore these.
我们的数据显示,在过去三个月内有一些内部购买,但没有卖出。那么,这些购买并不大。然而,我们对过去一年的交易进行的分析令人振奋。虽然我们对内部交易没有担忧,但如果他们拥有更多TScan Therapeutics的股票,我们会更舒适一些。在了解内部人士的所有权和交易情况的同时,我们还必须考虑到股票面临的风险,在做出任何投资决策之前。在进行分析时,我们发现TScan Therapeutics存在两个警示信号,忽视这些是不明智的。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,您可能会在其他地方找到一项出色的投资。因此,请查看此免费的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。